Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Disc Medicine, Inc.IRON · Entity 2273 | Director | June 18, 2026 | June 23, 2026 |
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Director | March 05, 2026 | March 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Disc Medicine, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.79 · Expires 2036-06-17 | Direct | 6,212 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 6,212 · Balance 6,212 F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.
SUPERNUS PHARMACEUTICALS, INC.
Report date March 05, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,277 |
Ending reported balance
After 2026-03-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-03-05 · Sale · Disposed 10,000 · Balance 28,159 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.50 to $54.15. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Row 2 · 2026-03-06 · Exercise / conversion · Acquired 7,905 · Balance 36,064 Row 3 · 2026-03-06 · Sale · Disposed 8,787 · Balance 27,277 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.03. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.30 · Expires 2027-02-24 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-06 · Exercise / conversion · Disposed 7,905 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.50 to $54.15. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.03. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dimension Therapeutics, Inc.
Report date November 07, 2017 · Filed November 07, 2017
Section 16 reporting ended · disclosed 2017-11-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.85 · Expires 2025-08-11 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-11-07 · Disposition to issuer · Disposed 44,474 · Balance 0 F1: This stock option, which vests in equal monthly installments over 48 months beginning July 15, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2026-05-18 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-11-07 · Disposition to issuer · Disposed 32,069 · Balance 0 F2: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2027-05-24 | Direct | 0 |
Reported balance
After 2017-11-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-07 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option, which vests in equal monthly installments over 48 months beginning July 15, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.
F2: These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
F3: These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
MOMENTA PHARMACEUTICALS INC
Report date October 01, 2020 · Filed October 01, 2020
Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 1
1 source rowRow 1 · 2020-10-01 · Disposition to issuer · Disposed 14,090 · Balance 0 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.84 · Expires 2026-01-01 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.20 · Expires 2027-06-20 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-01 · Disposition to issuer · Disposed 11,207 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30 · Expires 2028-06-20 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-01 · Disposition to issuer · Disposed 8,855 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2029-06-19 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.09 · Expires 2030-06-23 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
F2: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Raptor Pharmaceutical Corp
Report date October 24, 2016 · Filed October 26, 2016
Section 16 reporting ended · disclosed 2016-10-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2016-10-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-10-24 · Other · Disposed 2,092 · Balance 8,330 F1: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent. Row 2 · 2016-10-25 · Disposition to issuer · Disposed 8,330 · Balance 0 F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2026-04-15 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-10-25 · Disposition to issuer · Disposed 7,915 · Balance 0 F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent.
F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes.
F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 20:59 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 6,212 | $0.00 Strike: $70.79 | $0.00 |
DisclosureSEC source: 0001193125-26-279712 · ownership.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,212 Underlying: Common Stock · 6,212 shares Expires 2036-06-17 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 06, 2026 Filed Mar 9, 2026 20:06 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 7,905 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001256088-26-000006 · wk-form4_1773086807.xml · derivative · entry 4 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,905 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2026 Filed Mar 9, 2026 20:06 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 8,787 | $53.00 | $465,711.00 |
DisclosureSEC source: 0001256088-26-000006 · wk-form4_1773086807.xml · nonDerivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,277 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.03. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 06, 2026 Filed Mar 9, 2026 20:06 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 7,905 | $25.30 | $199,996.50 |
DisclosureSEC source: 0001256088-26-000006 · wk-form4_1773086807.xml · nonDerivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:06 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 10,000 | $53.71 | $537,100.00 |
DisclosureSEC source: 0001256088-26-000006 · wk-form4_1773086807.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,159 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.50 to $54.15. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 21:36 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 4,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001256088-26-000004 · wk-form4_1772055360.xml · derivative · entry 4 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,475 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 21:36 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 4,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001256088-26-000004 · wk-form4_1772055360.xml · nonDerivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,159 Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:36 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001256088-26-000004 · wk-form4_1772055360.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:36 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 15,000 | $12.98 | $194,700.00 |
DisclosureSEC source: 0001256088-26-000004 · wk-form4_1772055360.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:45 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 4,977 | $0.00 Strike: $50.20 | $0.00 |
DisclosureSEC source: 0001256088-26-000002 · wk-form4_1771623910.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,977 Underlying: Common Stock · 4,977 shares Expires 2036-02-18 F3 · derivative.exercise_date: Each option vests on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:45 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 2,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001256088-26-000002 · wk-form4_1771623910.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,989 Underlying: Common Stock · 2,989 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 21:03 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $60.34 | $0.00 |
DisclosureSEC source: 0001193125-25-207557 · ownership.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2035-09-15 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2026 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 21:23 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $50.86 | $0.00 |
DisclosureSEC source: 0000950170-25-086384 · ownership.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2026 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| February 22, 2025 Filed Feb 24, 2025 22:45 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 5,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007463 · wk-form4_1740437106.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,369 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2025. F2 · derivative.expiration_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2025. Read SEC document |
| February 22, 2025 Filed Feb 24, 2025 22:45 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 5,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007463 · wk-form4_1740437106.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,684 Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:49 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 4,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007186 · wk-form4_1740174572.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,475 Underlying: Common Stock · 4,475 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:49 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,296 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001628280-25-007186 · wk-form4_1740174572.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,296 Underlying: Common Stock · 7,296 shares Expires 2035-02-19 F1 · derivative.exercise_date: The option vests on February 19, 2026. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:13 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 10,787 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001628280-24-047145 · wk-form4_1731445977.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,787 shares Expires 2025-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:13 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 10,787 | $36.30 | $391,568.10 |
DisclosureSEC source: 0001628280-24-047145 · wk-form4_1731445977.xml · nonDerivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,315 F1 · shares: The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.01 to $36.57. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 21:13 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 10,787 | $11.46 | $123,619.02 |
DisclosureSEC source: 0001628280-24-047145 · wk-form4_1731445977.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:11 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 14,213 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001628280-24-046666 · wk-form4_1731100311.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,787 Underlying: Common Stock · 14,213 shares Expires 2025-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:11 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 14,213 | $36.62 | $520,480.06 |
DisclosureSEC source: 0001628280-24-046666 · wk-form4_1731100311.xml · nonDerivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,315 F1 · shares: The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 23, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.50 to $36.89. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:11 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 14,213 | $11.46 | $162,880.98 |
DisclosureSEC source: 0001628280-24-046666 · wk-form4_1731100311.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2024 Filed Sep 17, 2024 20:10 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001628280-24-040598 · wk-form4_1726603841.xml · derivative · entry 4 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 10,000 shares Expires 2025-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2024 Filed Sep 17, 2024 20:10 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 10,000 | $31.33 | $313,300.00 |
DisclosureSEC source: 0001628280-24-040598 · wk-form4_1726603841.xml · nonDerivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,315 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.12 to $31.50. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| September 13, 2024 Filed Sep 17, 2024 20:10 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 10,000 | $11.46 | $114,600.00 |
DisclosureSEC source: 0001628280-24-040598 · wk-form4_1726603841.xml · nonDerivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2024 Filed Sep 17, 2024 20:10 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 3,886 | $31.33 | $121,748.38 |
DisclosureSEC source: 0001628280-24-040598 · wk-form4_1726603841.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,315 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.12 to $31.50. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $38.85 | $0.00 |
DisclosureSEC source: 0000950170-24-073673 · ownership.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2025 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 3,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028279 · tm247055-17_4seq1.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,886 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurred on February 23, 2024. F2 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurred on February 23, 2024. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 3,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028279 · tm247055-17_4seq1.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,201 Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 5,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027583 · tm247055-8_4seq1.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,369 Underlying: Common Stock · 5,369 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 8,252 | $0.00 Strike: $27.94 | $0.00 |
DisclosureSEC source: 0001104659-24-027583 · tm247055-8_4seq1.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,252 Underlying: Common Stock · 8,252 shares Expires 2034-02-22 F1 · derivative.exercise_date: The option vests on February 22, 2025. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 22:24 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 7,136 | $0.00 Strike: $45.69 | $0.00 |
DisclosureSEC source: 0000899243-23-015271 · doc4.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,136 Underlying: Common Stock · 7,136 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2024 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-026076 · tm237737-13_4seq1.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,886 Underlying: Common Stock · 3,886 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 23, 2024. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 23, 2024. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,293 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-23-026076 · tm237737-13_4seq1.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,293 Underlying: Common Stock · 6,293 shares Expires 2033-02-23 F1 · derivative.exercise_date: The option vests on February 23, 2024. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:14 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 3,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025380 · tm237737-4_4seq1.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,882 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2023. F2 · derivative.expiration_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:14 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 3,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025380 · tm237737-4_4seq1.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,315 Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 22:17 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0000899243-23-000318 · doc4.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2032-12-28 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026874 · tm227622-1_4seq1.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,882 Underlying: Common Stock · 3,882 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,847 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001104659-22-026874 · tm227622-1_4seq1.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,847 Underlying: Common Stock · 6,847 shares Expires 2032-02-22 Read SEC document |
| February 19, 2022 Filed Feb 23, 2022 21:17 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026103 · tm227492d3_4seq1.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,222 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2022. F2 · derivative.expiration_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2022. Read SEC document |
| February 19, 2022 Filed Feb 23, 2022 21:17 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026103 · tm227492d3_4seq1.xml · nonDerivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,433 Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:04 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 793,274 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-22-001628 · doc4.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director · Executive Chair of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 793,274 Underlying: Common Stock · 793,274 shares Expires 2032-01-02 F1 · derivative.exercise_date: 50% of the Option Shares shall become exercisable on August 5, 2022 and the remaining 50% of the Option Shares shall become exercisable on August 5, 2023. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 12:56 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 17,245 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0000899243-21-044718 · doc4.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,245 Underlying: Common Stock · 17,245 shares Expires 2031-11-14 F2 · derivative.exercise_date: 100% of the option shall vest on the earlier of (a) the one-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 12:56 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 23,514 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0000899243-21-044718 · doc4.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,514 Underlying: Common Stock · 23,514 shares Expires 2031-11-14 F1 · derivative.exercise_date: 100% of the option shall vest on August 5, 2022 so long as the Optionee continues to have a Service Relationship with the Company on such date. Read SEC document |
| April 29, 2021 Filed May 3, 2021 20:02 UTC | Disc Medicine, Inc. GMTX · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 45,466 | $0.00 Strike: $11.92 | $0.00 |
DisclosureSEC source: 0001213900-21-024226 · ownership.xml · derivative · entry 1 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,466 Underlying: Common Stock · 45,466 shares Expires 2031-04-28 F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of three years from the Vesting Start Date, April 29, 2021, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting in eight quarterly installments thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:48 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-026929 · tm217706-4_4seq1.xml · derivative · entry 3 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,222 Underlying: Common Stock · 4,222 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These shares will be settled in common stock upon vesting, such vesting to occur on February 19, 2022. F2 · derivative.expiration_date: These shares will be settled in common stock upon vesting, such vesting to occur on February 19, 2022. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:48 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,365 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001104659-21-026929 · tm217706-4_4seq1.xml · derivative · entry 2 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,365 Underlying: Common Stock · 7,365 shares Expires 2031-02-19 Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:12 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $38.09 | Not disclosed |
DisclosureSEC source: 0001179110-20-010060 · edgar.xml · derivative · entry 6 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2030-06-23 F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 17:12 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $12.64 | Not disclosed |
DisclosureSEC source: 0001179110-20-010060 · edgar.xml · derivative · entry 5 GEMAYEL GEORGES · CIK 0001256088 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2029-06-19 F2 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F2 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.